Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Al-Tamari HM, Dabral S, Schmall A, Sarvari P, Ruppert C, Paik J, et al. FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. EMBO Mol Med. 2018;10(2):276-293.

McIntire PJ, Snow JT, Robinson BD, Rao RA, Goyal A, Heymann JJ, et al. Improved correlation of urinary cytology specimens using The Paris System in biopsy-proven upper tract urothelial carcinomas. Cancer Cytopathol. 2018;126(7):498-504.

Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, et al. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Sci Rep. 2018;8(1):7189.

Ooki A, Dinalankara W, Marchionni L, Tsay J-, Goparaju C, Maleki Z, et al. Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma. Oncogene. 2018;37(45):5967-5981.

Orleans RA, Magro CM, Varghese GI. A case of granuloma annulare mimicking tinea cruris. Dermatol Online J. 2018;24(8).

Zadra G, Loda M. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. Cold Spring Harb Perspect Med. 2018;8(10).

Lin E, Scognamiglio T, Zhao Y, Schwartz TH, Phillips CD. Prognostic Implications of Gadolinium Enhancement of Skull Base Chordomas. AJNR Am J Neuroradiol. 2018;39(8):1509-1514.

Tabbo F, Nottegar A, Guerrera F, Migliore E, Luchini C, Maletta F, et al. Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. Hum Pathol. 2018;75:167-178.

Gafeer MM, Mohammed KH, Ormenisan-Gherasim C, Choudhary F, Siddiqui MT, Cohen C. Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma: Immunohistochemistry and RNA In Situ Hybridization. Appl Immunohistochem Mol Morphol. 2018;26(8):e86-e90.

Baker TM, Rogers W, Chavda KD, Westblade LF, Jenkins SG, Nicolau DP, et al. Epidemiology of Bloodstream Infections Caused by and That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible. Open Forum Infect Dis. 2018;5(12):ofy300.